Genfit S.A.
- BID
14.08
- ASK
14.1
- 90 Units89 Units
- 07/21, 21:59:29 PM
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
296.24%
Market Cap
-
P/E Ratio
0.00
Dividend Yield
0.00 %
Earnings per Share
-1.72 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 14.08 G | 0 Units |
| PRICE DETERMINATION TIME | 07/21/2026 / 09:56:42 PM | |
| DAILY VOLUME (UNITS) | 14,993 | |
| DAILY HIGH / LOW | 14.12 | 13.56 |
| PREV. DAY'S PRICE | 13.48 | (07/20) |
| CHANGE DAY BEFORE | +0.60 | 4.45 % |
| 52 WEEK HIGH / LOW | 14.24 (07/08) | 2.848 (09/26) |
Key Figures (in EUR)
| 2023 | 2024 | 2025 | 2026e | 2027e | |
|---|---|---|---|---|---|
EARNINGS PER SHARE | -0.58 | 0.03 | -1.72 | 0.37 | 0.18 |
DIVIDENDS PER SHARE | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
DIVIDEND YIELD IN % | 0.00 % | 0.00 % | 0.00 % | - | - |
DIVIDEND GROWTH IN % | - | - | - | - | - |
PRICE - EARNINGS RATIO | - | 116.67 | - | 36.73 | 75.33 |
PRICE - BOOK RATIO | 2.61 | 2.56 | - | - | - |
PRICE - SALES RATIO | 6.16 | 2.64 | 4.01 | - | - |
PRICE - CASH FLOW RATIO | - | 11.61 | - | - | - |
Master Data
| WKN | A0LGJ2 |
| ISIN | FR0004163111 |
| SYMBOL | XUP |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | GENFIT S.A. EO -,25 |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | - |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | - |
| MARKET CAPITALISATION | - |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | 0.60 % | 25.75 % | 48.62 % | 161.75 % | 296.24 % | 276.54 % | 333.44 % | 164.31 % |
| HIGH | 13.82 | 14.24 | 14.24 | 14.24 | 14.24 | 14.24 | 14.24 | 14.24 |
| LOW | 12.42 | 9.10 | 7.79 | 5.06 | 2.85 | 1.37 | 1.37 | 5.06 |
Dividende
pro Aktie
GENFIT S.A. EO -,25 does not deliver dividend information
Company profile
Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company focuses on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatments. It focuses on medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver. The company was founded by Jean-François Mouney, Florence Séjourné, and Bart Staels in September 1999 and is headquartered in Loos, France.
Structured products for Genfit S.A.
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
No company events available.